The therapeutic potential of recombinant human interleukin-11 (rhIL-11) was tested in a neutropenic rat model that mimics the clinical consequences of myelosuppressive chemotherapy complicated by Pseudomonas aeruginosa sepsis. rhIL-11 -treated animals (150 mg/kg intravenously every 24 h for 3 days) had reduced endotoxin levels (P õ .05) and less pulmonary edema fluid (P õ .001) and were protected (P õ .01) against thinning and necrosis of the intestinal mucosa compared with the control group. The survival rate in rhIL-11 -treated animals was 40% (19/47), whereas it was 0 (0 of 19) in the control group (P õ .01). The addition of ciprofloxacin (10 mg/kg every 12 h) resulted in a survival rate of 9 (60%) of 15, while the combination of rhIL-11 and ciprofloxacin resulted in 100% survival (15/15; P õ .05). These results indicate that rhIL-11 supports mucous membrane integrity of the alimentary tract and decreases the systemic inflammatory response to experimental gram-negative infection in immunocompromised animals.
Optimal regimens for the prevention and treatment of sepsis inhibitor of metalloproteinase-1, attenuates the proinflammatory cytokine response [9] , and improves cardiovascular funcin the immunocompromised host have yet to be developed, despite substantial advances in the supportive care of such tion during endotoxemia in rabbits [10] .
In the current investigation, recombinant human (rh) IL-11 patients. Hematopoietic growth factors have significantly improved the management of myelosuppressed patients [1] , while was tested in the neutropenic rat model of experimental gramnegative sepsis. This model mimics the series of pathoattempts to disrupt the pathophysiology of sepsis with immunomodulatory agents have met with uncertain and generally disapphysiologic events that may accompany the administration of cytoreductive chemotherapy [2] . This subacute infection model pointing results [2] .
The recently described pleiotropic cytokine, interleukin-11 results in an endogenously mediated bacteremic infection from Pseudomonas aeruginosa from the gastrointestinal tract of (IL-11) [3] , has a number of favorable attributes that could be exploited as a potential treatment strategy in bacterial sepsis these animals. The efficacy of rhIL-11 alone or in combination with systemic antimicrobial agents was tested in this experiin the immunocompromised host [4] . In addition to its action as a hematopoietic growth factor, IL-11 has been shown to mental system. enhance survival in animals treated with cytoablative chemotherapy and radiation therapy [5, 6] . IL-11 protects the mucosal integrity of the alimentary tract from cytotoxic agents and sigMaterials and Methods nificantly improves the outcome in experimental models of Animal models. The methods used in the neutropenic rat model chronic inflammatory bowel disease [7] . Recombinant human of P. aeruginosa sepsis have been described previously [2] . Briefly, IL-11 has recently been shown to be protective in a staphyloSprague-Dawley rats (Charles River Breeding Laboratories, Wilcoccal toxic shock model [8] . IL-11 supports the synthesis mington, MA) are colonized with a virulent, serum-resistant strain of the acute-phase proteins, stimulates the synthesis of tissue of P. aeruginosa (strain 12.4.4, Fisher-Devlin-Gnabasik immunotype 6) by orogastric feeding at 10 6 cfu/mL (1 mL) every other day for three doses. Cefamandole (Eli Lilly, Indianapolis) was given at 100 mg/kg (intramuscularly) to disrupt colonization resis-Xoma, Berkeley, CA]) (n Å 19); ciprofloxacin (10 mg/kg) orally significantly differ between ciprofloxacin alone or rhIL-11 every 12 h for 3 days (n Å 15); or rhIL-11 in combination with treatment alone. However, the combination of ciprofloxacin ciprofloxacin (n Å 15). A preliminary study found that ciprofloxaand rhIL-11 significantly improved outcome over either treatcin was highly effective against P. aeruginosa 12.4.4, with a MIC ment alone (P õ .01). of 0.125 mg/mL. Each animal had a series of blood specimens
The mucosal mass of the intestinal epithelium was preserved obtained during the pretreatment phase and then at the onset of in rhIL-11 -treated animals compared with the placebo group fever and 24 h after the initial febrile response. All animal manipu- (table 1) . Preliminary experiments in normal (nonneutropenic) lations were done under light CO 2 anesthesia. P. aeruginosa isorats found that the mucosal mass was not significantly affected
lates from animal tissues were tested with typing sera, and immuby rhIL-11 treatment: 12.1 mg/cm (11.2 -13.9 mg/cm) for connotype 6 isolates were considered to be the challenge strain of P.
trols (n Å 10) versus 13.2 mg/cm (11.6 -14.5 mg/cm) for IL- experiments. However, rhIL-11 primarily stimulates platelet recovery, and no significant increase in neutrophil count was A Kaplan-Meier plot of the four treatment arms of the study is shown in figure 1 . The results are derived from a series detected in these experiments. rhIL-11 belongs to a family of cytokines that are collectively of three experiments: experiment 1 (IL-11, n Å 23; control, n Å 11), experiment 2 (rhIL-11, n Å 12; IL-11 / ciprofloxacin, referred to as gp130 receptor ligands or IL-6 -like cytokines [12] . These cytokines collectively use the gp130 signal transn Å 7; ciprofloxacin, n Å 8; control, n Å 4), and experiment 3 (rhIL-11, n Å 12; IL-11 / ciprofloxacin, n Å 8; ciprofloxacin, duction pathway at the cell surface of target cells. rhIL-11 is known to possess antiinflammatory cytokine activity in that n Å 7; control, n Å 4). Animals randomized to the control group (n Å 19) developed a uniformly fatal bacteremic infection the administration of rhIL-11 in vitro is known to diminish the rate of synthesis of TNF-a, interferon-g, IL-1, and the p40 with P. aeruginosa, with multisystem infection and multiorgan failure. Therapeutic administration of rhIL-11 at the onset of subunit of IL-12. These antiinflammatory properties have been attributed to the ability of IL-11 to increase IkB-a and IkB-b fever resulted in a significantly improved survival (19/47 [40%]; P õ .01). Therapeutic administration of ciprofloxacin synthesis in activated macrophages. These regulatory elements bind to NF-kB and block the nuclear translocation of NF-kB also resulted in an improved survival (9/15 [60%]; P õ .01) compared with the control group. The combination of cias a proinflammatory cytokine gene activator [9] . Nitric oxide production from peritoneal macrophages was diminished by profloxacin and rhIL-11 resulted in a survival rate of 100% (15/15; P õ .001). The overall duration of survival did not ú50% by rhIL-11 treatment. Biologically active levels of TNF / 9d52$$oc31 09-01-98 19:36:50 jinfa UC: J Infect were also diminished in this infection model of bacteremic P. Recombinant human IL-11 has other potential benefits in the setting of systemic bacterial infection [4, 8] . rhIL-11 is aeruginosa sepsis. The down-regulation of the proinflammatory cytokines by the inhibitory action of IL-11 may protect known to promote the synthesis of an inhibitor of metalloproteinases, which may limit damage to tissues in inflammatory the host from the injurious effects of excess cytokine production seen in the course of systemic bacterial infections [8] .
disorders. rhIL-11 also supports B cell differentiation and immunoglobulin synthesis, which may assist in the clearance of rhIL-11 treatment resulted in remarkable preservation of the intestinal epithelium in these neutropenic animals. Increased bacterial pathogens in immunocompromised animals. The added benefit of rhIL-11 to antimicrobial therapy in permeability of the gastrointestinal mucosa following systemic injury may lead to bacteremia from enteric microflora and enthese neutropenic animals is of considerable interest. This suggests that rhIL-11 may function as a immunoadjuvant to comdotoxemia by the process of translocation [13, 14] . While the integrity of gastrointestinal mucosa was largely preserved by plement the antibiotic treatment used in clinical management of neutropenic patients. Recombinant human IL-11 has been rhIL-11 in these experiments, bloodstream infection continued to occur. However, circulating levels of endotoxin were sigtested in myelosuppressed patients with malignancies and has been well-tolerated in clinical trials thus far [15] . nificantly reduced in the rhIL-11 treatment groups. The maintenance of the barrier function in the alimentary tract may be an In summary, rhIL-11 provides a survival benefit in this model of bacteremic P. aeruginosa infection in neutropenic important therapeutic effect of rhIL-11 in the severely immunocompromised host. It is anticipated that this effect of IL-11 animals. The benefits accrued by rhIL-11 may include its antiinflammatory effects and its protective effects on gastrointestimay be useful in the treatment of other inflammatory disorders of the gastrointestinal tract [7] . nal membrane integrity. The incremental benefits of rhIL-11 Table 1 . Results of rhIL-11 and ciprofloxacin treatment. NOTE. Data are results of blood samples 24 h after onset of fever, expressed as median (25% -75% interquartile range).
* P õ .001 vs. controls. † P õ .01 vs. controls. ‡ P õ .05 vs. controls.
